NCAM1 and breast cancer: Breast cancer patients with higher levels of CD3-CD16+CD56+ cells in peripheral blood demonstrated significantly improved OS (Figure 3C) and RFS compared to those with lower levels (both P < 0.001) (Figure 3D).